Omeros
®
and the Omeros logo
®
are registered trademarks, and Omidria
™
and the Omidria logo
™
are trademarks, of Omeros Corporation. © Omeros Corporation 2015, all rights reserved. 2014-128
CMS PASS-THROUGH STATUS EFFECTIVE JANUARY 1, 2015
OMIDRIA
™
is reimbursed by the Centers for Medicare and Medicaid
Services (CMS)
OMIDRIA has been granted transitional pass-through payment status under
the Medicare hospital outpatient prospective payment system (OPPS)
Pass-through status allows for payment for OMIDRIA separate from
the bundled Ambulatory Payment Classifi cation (APC) payment
For more information about OMIDRIA, including how to order or to obtain
reimbursement, contact 1-844-OMEROS1 (1-844-663-7671) or visit omidria.com.
IMPORTANT SAFETY INFORMATION
OMIDRIA must be diluted prior to intraocular use.
OMIDRIA is contraindicated in patients with a known hypersensitivity to any
of its ingredients.
Systemic exposure of phenylephrine may cause elevations in blood pressure.
Use OMIDRIA with caution in individuals who have previously exhibited sensitivities
to acetylsalicylic acid, phenylacetic acid derivatives, and other non-steroidal
anti-infl ammatories (NSAIDs), or have a past medical history of asthma.
The most common reported ocular adverse reactions at 2–24% are eye irritation,
posterior capsule opacifi cation, increased intraocular pressure, and anterior
chamber infl ammation.
Use of OMIDRIA in children has not been established.
Please see full prescribing information for OMIDRIA
at www.omidria.com/prescribinginformation.
You are encouraged to report negative side effects of
prescription drugs to the FDA. Visit www.fda.gov/medwatch,
or call 1-800-FDA-1088.
Reference: 1. OMIDRIA [package insert]. Seattle, WA: Omeros Corporation; 2014.
